Miranda Lankas

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Treatment with darolutamide decreased the likelihood of developing metastatic disease or discontinuing treatment because of adverse effects vs treatment with apalutamide or enzalutamide in patients with non-metastatic castration-resistant prostate cancer.

Iberdomide monotherapy or in combination with anti-CD20 antibodies was well tolerated and found to elicit encouraging responses in patients with relapsed or refractory lymphoma.

Chemotherapy prior to treatment with endocrine therapy could increase the risk of cancer-related cognitive impairment compared with endocrine therapy alone in women with breast cancer, irrespective of menopausal status.

Pembrolizumab plus abiraterone acetate and prednisone demonstrated continued efficacy and tolerability in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.